Diaccurate Appoints Scott Filosi as CEO Our Oral Optimized S6 Kinase Inhibitor Is Now Rupitasertib Our Selective KIF20A Inhibitor is now EVX-020 Latest news Evexta Bio Appoints Edith A. Perez as Scientific Advisor October 25, 2024 Evexta Bio appoints Robert Doebele as CMO consultant July 29, 2024 Evexta Bio appoints Shawn M. Leland as Chairman of the Board of Directors June 19, 2024 Upcoming events
